Yes. In 2020 December it was still clinical stage company. We all know that from doing our DD. They catch the retail that does none (caught one on here lol). Not sure about Q4 numbers. I'm hoping we hit $21m at the lowest. It would put them right at their guidance of $40 - $50m for 2021. Looking forward to 2022 guidance. And of course I bought more shares today.
Market Data 
Markets 
AI
